One last thing, as it came up as a question in the podcast and also from a couple of posters on this board in the last few days and that is, what is the clinical trials outlook in AD, given the problems with the Aduhelm launch and is that going to have an effect on drug development/investment targeting AD.
Anyone who has any concerns in this regard or does not comprehend the huge 10 to 15 year tail wind that Cogstate now has at its back would benefit by investing 50mins to listen to the following podcast.
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)